Patent ID: 7560121

Claim:
A transdermal therapeutic system consisting essentially of: a) a backing layer, b) at least one active substance-containing polymer matrix layer, which has or has not at the same time pressure sensitive adhesive properties; c) at least one permeation enhancer; d) at least one basic auxiliary substance which is a basic polymer; and e) a pressure-sensitive adhesive layer on a skin-facing side of the matrix layer in case the matrix layer does not have pressure-sensitive adhesive properties; wherein the active substance is at least one neuroleptic selected from the group consisting of a pharmaceutically acceptable salt of fluphenazine, a pharmaceutically acceptable salt of flupentixol and a pharmaceutically acceptable salt of triflupromazine, wherein the permeation enhancer is selected from the group consisting of saturated fatty acids, mono-unsaturated fatty acids, saturated fatty alcohols and unsaturated fatty alcohols, each having 6 to 18 carbon atoms, and wherein said polymer matrix layer having pressure sensitive adhesive properties and said pressure sensitive adhesive respectively are based on polymers comprising pure hydrocarbons.